World's Best Scientists 2026 revealed!
Award Badge
Medicine
Germany
2026

D-Index & Metrics

Medicine

D-Index
134
Citations
63598
World Ranking
2158
National Ranking
104

Research.com Recognitions

  • 2026 - Research.com Medicine in Germany Leader Award
  • 2023 - Research.com Medicine in Germany Leader Award

Overview

Hermann Einsele is affiliated with the University of Würzburg in Germany. Their research primarily focuses on medical fields related to hematology, immunology, molecular biology, oncology, and epidemiology.

The scientist's main research topics include:

  • CAR-T cell therapy research
  • Immune Cell Function and Interaction
  • Protein Degradation and Inhibitors
  • Cytomegalovirus and herpesvirus research
  • Herpesvirus Infections and Treatments
  • Parvovirus B19 Infection Studies
  • Acute Myeloid Leukemia Research

Hermann Einsele has published extensively in the field of medicine, with 31 publications spanning related subfields such as immunology, epidemiology, molecular biology, oncology, and hematology. Their work has appeared frequently in several scientific journals and venues, including:

  • Blood (4 publications)
  • The Lancet Infectious Diseases (2 publications)
  • Best Practice & Research Clinical Haematology (2 publications)
  • Cell Death Discovery (1 publication)
  • Cellular Oncology (1 publication)

Notable papers authored by Hermann Einsele include:

  • How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation, 2020, Blood
  • Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia, 2022, The Lancet Infectious Diseases
  • Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies, 2025, The Lancet Infectious Diseases
  • Therapeutic advances in the targeting of ROR1 in hematological cancers, 2024, Cell Death Discovery
  • Looking ahead to targeting macrophages by CAR T- or NK-cells in blood cancers, 2024, Expert Opinion on Therapeutic Targets

Frequent co-authors collaborating with Hermann Einsele include:

  • Dávid Kegyes
  • Rafael de la Cámara
  • Adrian Bogdan Țigu
  • Raluca Munteanu
  • Diana Gulei

Best Publications

  • Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

    Marcie Tomblyn;Tom Chiller;Hermann Einsele;Ronald Gress

  • Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Nikhil C Munshi;Larry D Anderson;Nina Shah;Deepu Madduri

  • The landscape of genomic alterations across childhood cancers

    Susanne N. Gröbner;Barbara C. Worst;Joachim Weischenfeldt;Joachim Weischenfeldt;Ivo Buchhalter

  • Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

    Abstr Act;Sagar Lonial;Meletios Dimopoulos;Antonio Palumbo

  • Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

    Ralf Bargou;Eugen Leo;Gerhard Zugmaier;Matthias Klinger

  • Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

    Max S. Topp;Peter Kufer;Nicola Gökbuget;Mariele Goebeler

  • Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

    Jesús F. San-Miguel;Vânia T.M. Hungria;Sung Soo Yoon;Meral Beksac

  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

    Pieter Sonneveld;Hervé Avet-Loiseau;Sagar Lonial;Saad Usmani

  • Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy.

    Hermann Einsele;Eddy Roosnek;Nathalie Rufer;Christian Sinzger

  • Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

    Jürgen Finke;Wolfgang A Bethge;Claudia Schmoor;Hellmut D Ottinger

  • Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer

    Volker Heinemann;Detlef Quietzsch;Frank Gieseler;Michael Gonnermann

  • Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

    Antonio Palumbo;Sara Bringhen;Maria Victoria Mateos;Alessandra Larocca

  • Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).

    Roswitha Forstpointner;Michael Unterhalt;Martin Dreyling;Hans-Peter Böck

  • Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation.

    Tobias Feuchtinger;Kathrin Opherk;Wolfgang A. Bethge;Max S. Topp

  • Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

    Max S. Topp;Nicola Gökbuget;Gerhard Zugmaier;Evelyn Degenhard

  • Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study

    Peter Reimer;Thomas Rüdiger;Eva Geissinger;Florian Weissinger

  • Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

    Nicolaus Kröger;Ernst Holler;Guido Kobbe;Martin Bornhäuser

  • Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

    Michele Cavo;Evangelos Terpos;Cristina Nanni;Philippe Moreau

  • Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

    Christoph Röllig;Hubert Serve;Andreas Hüttmann;Richard Noppeney

  • The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells

    Katrin Mestermann;Theodoros Giavridis;Justus Weber;Julian Rydzek

Frequent Co-Authors

Holger Hebart
Holger Hebart University of Tübingen
Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
Lothar Kanz
Lothar Kanz University of Tübingen
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Stefan W. Krause
Stefan W. Krause University of Erlangen-Nuremberg
Andreas Rosenwald
Andreas Rosenwald University of Würzburg
Hartmut Goldschmidt
Hartmut Goldschmidt University Hospital Heidelberg
Michele Cavo
Michele Cavo University of Bologna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring allied health fields or support roles can be a smart way to begin your medical career. Many choose to start with in-demand programs like the best medical billing and coding schools online, which offer flexible schedules and financial aid for those interested in the administrative side of healthcare.

Nursing also remains a highly rewarding field, with a growing number of accessible options. For example, there are now lpn to rn programs without teas test requirements, making it easier for Licensed Practical Nurses to advance their credentials quickly.

Aspiring healthcare leaders can accelerate their careers through a health care administration degree online, designed for those looking to enter management roles within hospitals, clinics, or insurance companies.

Registered Nurses who wish to become Family Nurse Practitioners may consider specialized adn to fnp bridge programs that offer a streamlined pathway to advanced practice.

These online pathways are ideal for students and working professionals who need flexibility as they build careers in the ever-evolving healthcare field.

Best Scientists Citing Hermann Einsele

Trending Scientists

Recently Published Articles